Latest thoughts from Double Blind Bio

With fragmented data and no easy way to compare site performance, sponsors often default to familiar choices instead of the best ones.

Clinical trials depend on fast enrollment and reliable site performance. Yet, sponsor-site decisions often fail to reflect these priorities.

GLP-1 drugs are transforming metabolic health, paving the way for a rich pipeline of therapies that push the boundaries of what’s possible.